Study compares apomorphine and ropinirole for canine emesis

CURRENT BRIEF VERSION: A new 2025 study is giving clinicians fresh head-to-head data on two familiar emetic options in dogs: intravenous apomorphine and ophthalmic ropinirole. In a randomized crossover trial in 24 healthy dogs, investigators found both drugs were highly effective for inducing emesis, with success rates of 95.8% for apomorphine and 100% for ropinirole, with no significant difference in overall efficacy. The tradeoff was speed and adverse effect profile: apomorphine worked faster, with a median onset of 1.18 minutes versus 8.85 minutes for ropinirole, while ropinirole was associated with more ocular redness and more protracted vomiting. Ropinirole, marketed as Clevor, remains the only FDA-approved emetic for dogs in the U.S., while apomorphine is still used extra-label. (frontiersin.org)

Why it matters: For veterinary teams managing toxin or foreign-body ingestions, the study helps sharpen a practical choice that often comes down to workflow, access, and patient factors. That question is especially relevant in emergency practice, where a separate 2025 prospective randomized clinical trial in 132 client-owned dogs at two specialty hospitals compared ropinirole eye drops with IV apomorphine after suspected or confirmed toxin or foreign-body ingestion. In that real-world ER population, dogs that did not vomit within 20 minutes received a second identical dose and were monitored for 40 minutes, with rescue antiemetics used when needed after successful emesis. Apomorphine may still appeal when speed is the priority and IV access is already in place, but ropinirole offers an approved, needle-free option that avoids compounding and has shown strong effectiveness in both the FDA field study and recent comparative research. The decision is less about whether either drug works, and more about which one fits the patient, the clinic setup, and the risk of ocular irritation, prolonged vomiting, or handling concerns. (frontiersin.org; pubmed.ncbi.nlm.nih.gov)

What to watch: Expect more discussion around real-world use in emergency settings, especially as clinicians weigh the newer healthy-dog data against that emergency-practice study, which enrolled dogs with suspected or confirmed ingestion of toxic foods, plants, medications, rodenticides, foreign material, and cloth items and reported faster, more reliable first-dose success with apomorphine. Also worth watching on the supportive-care side: Dechra says its newly FDA-approved maropitant injectable, Emeprev, a bioequivalent to the leading antiemetic, will be available through major distributors in early 2026, with no refrigeration required and reduced injection discomfort in dogs due to benzyl alcohol in the formulation. (pubmed.ncbi.nlm.nih.gov)